1557084-70-4

Upstream product

• 1557084-43-1 3-(2-chloro-4-morpholinopyrido[3,2-d]pyrimidin-7-yl)aniline 
• 1557084-46-4 tert-butyl (5-(7-(3-aminophenyl)-4-morpholinopyrido[3,2-d]pyrimidin-2-yl)pyrimidin-2-yl)carbamate 
• 17341-93-4 2,2,2-Trichloroethyl chloroformate 
• 573675-25-9 5-bromo-3-nitropyridine-2-carbonitrile 
• 669066-89-1 3-amino-5-bromopyridine-2-carboxylic acid amide 
• 870997-85-6 3-amino-5-bromo-pyridine-2-carboxylic acid 
• 1215074-41-1 7-bromo-2,4-dichloropyrido[3,2-d]pyrimidine 
• 1374208-53-3 4-(7-bromo-2-chloropyrido[3,2-d]pyrimidin-4-yl)morpholine 

Relevant academic research and scientific papers

Substituted Amino-Pyrimidine Derivatives

The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts, prodrugs, and solvates thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.